BIO.B Stock Overview
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Bio-Rad Laboratories, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$332.20 |
52 Week High | US$467.95 |
52 Week Low | US$271.00 |
Beta | 0.87 |
1 Month Change | -5.87% |
3 Month Change | 3.60% |
1 Year Change | -28.42% |
3 Year Change | -42.66% |
5 Year Change | 9.64% |
Change since IPO | 13,646.21% |
Recent News & Updates
Shareholder Returns
BIO.B | US Life Sciences | US Market | |
---|---|---|---|
7D | 0% | 1.0% | 2.1% |
1Y | -28.4% | 5.9% | 30.4% |
Return vs Industry: BIO.B underperformed the US Life Sciences industry which returned 6.8% over the past year.
Return vs Market: BIO.B underperformed the US Market which returned 31.1% over the past year.
Price Volatility
BIO.B volatility | |
---|---|
BIO.B Average Weekly Movement | n/a |
Life Sciences Industry Average Movement | 7.2% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BIO.B has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BIO.B's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1952 | 8,030 | Norman Schwartz | https://www.bio-rad.com |
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.
Bio-Rad Laboratories, Inc. Fundamentals Summary
BIO.B fundamental statistics | |
---|---|
Market cap | US$9.94b |
Earnings (TTM) | -US$637.32m |
Revenue (TTM) | US$2.67b |
3.8x
P/S Ratio-15.8x
P/E RatioIs BIO.B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BIO.B income statement (TTM) | |
---|---|
Revenue | US$2.67b |
Cost of Revenue | US$1.24b |
Gross Profit | US$1.43b |
Other Expenses | US$2.07b |
Earnings | -US$637.32m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -22.35 |
Gross Margin | 53.56% |
Net Profit Margin | -23.86% |
Debt/Equity Ratio | 13.6% |
How did BIO.B perform over the long term?
See historical performance and comparison